LEADER 02437nam 2200565 a 450 001 9910140554903321 005 20170809163703.0 010 $a3-527-64467-9 010 $a1-283-14044-6 010 $a9786613140449 010 $a3-527-63007-4 010 $a3-527-63008-2 035 $a(CKB)2670000000019017 035 $a(EBL)530455 035 $a(OCoLC)630542399 035 $a(SSID)ssj0000430139 035 $a(PQKBManifestationID)11965379 035 $a(PQKBTitleCode)TC0000430139 035 $a(PQKBWorkID)10453602 035 $a(PQKB)10919303 035 $a(MiAaPQ)EBC530455 035 $a(EXLCZ)992670000000019017 100 $a20100612d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aTuberous sclerosis complex$b[electronic resource] $egenes, clinical features and therapeutics /$fedited by David J. Kwiatkowski, Vicky Holets Whittemore, and Elizabeth A. Thiele 210 $aWeinheim $cWiley-Blackwell$d2010 215 $a1 online resource (433 p.) 300 $aDescription based upon print version of record. 311 $a3-527-32201-9 320 $aIncludes bibliographical references and index. 327 $apt. 1. Basics -- pt. 2. Genetics -- pt. 3. Basic sciences -- pt. 4. Brain involvement -- pt. 5. Other organ systems -- pt. 6. Family impact. 330 $aThe only comprehensive overview of the molecular basis and clinical features of the genetic disorder tuberous sclerosis, which affects approximately 50,000 people in the US alone. Special focus is placed on novel insights into the signal transduction pathways affected by the disease as well as genotype phenotype correlations, while existing and potential therapies are also discussed in depth. The editors are leading experts in research and treatment of the disease as well as the Vice President of the Tuberous Sclerosis Alliance, the only voluntary health organization for TSC in the US. 606 $aTuberous sclerosis 608 $aElectronic books. 615 0$aTuberous sclerosis. 676 $a616.8 701 $aKwiatkowski$b David J$0951608 701 $aWhittemore$b Vicky Holets$0870111 701 $aThiele$b Elizabeth A$0951609 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910140554903321 996 $aTuberous sclerosis complex$92151325 997 $aUNINA